Skip to main content

ICICI Bank likely to see significant jump in Q2 profit, but loan growth may slow down

Net interest income is expected to be more than 12 percent year-on-year with slowing down loan growth to around 5-6 percent YoY, but deposits growth could be around 18-20 percent YoY.

The country's second largest private sector lender, ICICI Bank, on October 31, is expected to report significant year-on-year growth in September quarter profit due to low base in the year-ago period. In Q2FY20, profit was affected by deferred tax assets hit following change in corporate tax rate by the government.

Profit is likely to be in the wide range of Rs 3,000-4,000 crore against Rs 655 crore in same period last year. Provisions may remain elevated on year-on-year basis, but the sequentially may decline as the bank already made high contingent provisions for likely COVID-19 related defaults.

Net interest income is expected to be more than 12 percent year-on-year with slowing down loan growth to around 5-6 percent YoY, but deposits growth could be around 18-20 percent YoY.

"We expect a pre-provision operating profit (PPoP) growth of around 15 percent YoY with NII growth at 12 percent YoY partly aided by operating leverage. Loan growth to slow to around 6 percent but NIM (core) to remain stable QoQ at 3.7 percent," said Kotak Institutional Equities which sees 547.6 percent YoY growth in Q2 profit.

"We expect provisions to remain high but lower than the previous quarter as we don't see the bank making the same quantum of contingent provisions as we saw in Q1FY21. We expect focus to remain on the expected restructuring by Q4FY21," the brokerage added.



HDFC Securities also expects loan growth to slow further to 5.7 percent YoY, and core earnings to grow at 13 percent YoY.

Incremental COVID-19 related provisions, comments on collection efficiency, and movement in BB and below-rated book and outlook on asset quality (including restructuring) would be key factors to watch out for, said the brokerage.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...